Elevai Labs, Inc. Common Stock (ELAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has a cash flow conversion efficiency ratio of -0.119x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($16.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ELAB stock market capitalisation for the company's overall valuation and market capitalisation.
Elevai Labs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elevai Labs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is Elevai Labs, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acdc Metals Ltd
AU:ADC
|
10.897x |
|
TAIZHOU WATER GRP. H YC 1
F:GX5
|
N/A |
|
Adeunis
PA:ALARF
|
0.734x |
|
BIOVAXYS TECHNOLOGY CORP.
F:5LB
|
N/A |
|
PHOENIX COPPER LTD.
F:5HR
|
N/A |
|
Enrg Elements Ltd
AU:EEL
|
-0.578x |
|
AS Rigas kugu buvetava
STU:UW3
|
-0.045x |
|
LM Funding America Inc
NASDAQ:LMFA
|
-0.181x |
Annual Cash Flow Conversion Efficiency for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Elevai Labs, Inc. Common Stock from 2020 to 2025. View ELAB live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.84 Million | $-5.93 Million | -0.757x | +8.11% |
| 2024-12-31 | $6.66 Million | $-5.49 Million | -0.824x | +30.80% |
| 2023-12-31 | $3.83 Million | $-4.56 Million | -1.191x | +15.06% |
| 2022-12-31 | $1.13 Million | $-1.59 Million | -1.402x | +4.42% |
| 2021-12-31 | $450.63K | $-660.93K | -1.467x | -115.93% |
| 2020-12-31 | $-23.59K | $-217.16K | 9.206x | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing … Read more